GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Theriva Biologics Inc (AMEX:TOVX) » Definitions » E10

Theriva Biologics (Theriva Biologics) E10 : $-67.67 (As of Mar. 2024)


View and export this data going back to 1993. Start your Free Trial

What is Theriva Biologics E10?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

Theriva Biologics's adjusted earnings per share data for the three months ended in Mar. 2024 was $-0.300. Add all the adjusted EPS for the past 10 years together and divide 10 will get our e10, which is $-67.67 for the trailing ten years ended in Mar. 2024.

During the past 3 years, the average E10 Growth Rate was 11.40% per year. During the past 5 years, the average E10 Growth Rate was 7.80% per year. During the past 10 years, the average E10 Growth Rate was 15.90% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the E10 growth rate using E10 data.

During the past 13 years, the highest 3-Year average E10 Growth Rate of Theriva Biologics was 50.00% per year. The lowest was 3.40% per year. And the median was 23.20% per year.

As of today (2024-05-16), Theriva Biologics's current stock price is $0.3748. Theriva Biologics's E10 for the quarter that ended in Mar. 2024 was $-67.67. Theriva Biologics's Shiller PE Ratio of today is .


Theriva Biologics E10 Historical Data

The historical data trend for Theriva Biologics's E10 can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Theriva Biologics E10 Chart

Theriva Biologics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
E10
Get a 7-Day Free Trial Premium Member Only Premium Member Only -102.70 -101.84 -96.23 -80.87 -70.82

Theriva Biologics Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
E10 Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -80.01 -78.16 -75.19 -70.82 -67.67

Competitive Comparison of Theriva Biologics's E10

For the Biotechnology subindustry, Theriva Biologics's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Theriva Biologics's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Theriva Biologics's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Theriva Biologics's Shiller PE Ratio falls into.



Theriva Biologics E10 Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. When we calculate the today's Shiller P/E ratio of a stock, we use today's price divided by E10.

What is E10? How do we calculate E10?

E10 is the average of the inflation adjusted earnings of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the E10 of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the earnings from 2001 through 2010.

We adjusted the earnings of 2001 earnings data with the total inflation from 2001 through 2010 to the equivalent earnings in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart earned $1 a share in 2001, then the 2001's equivalent earnings in 2010 is $1.4 a share. If Wal-Mart earns $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 earnings in 2010 is $1.35. So on and so forth, you get the equivalent earnings of past 10 years. Then you add them together and divided the sum by 10 to get E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Theriva Biologics's adjusted earnings per share data for the three months ended in Mar. 2024 was:

Adj_EPS= Earnings per Share (Diluted) /CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=-0.3/131.7762*131.7762
=-0.300

Current CPI (Mar. 2024) = 131.7762.

Theriva Biologics Quarterly Data

per share eps CPI Adj_EPS
201406 -28.000 100.560 -36.692
201409 -28.000 100.428 -36.740
201412 -31.501 99.070 -41.901
201503 -59.501 99.621 -78.706
201506 -66.501 100.684 -87.037
201509 -42.001 100.392 -55.131
201512 -42.320 99.792 -55.884
201603 -42.001 100.470 -55.088
201606 -35.001 101.688 -45.357
201609 -31.972 101.861 -41.362
201612 -7.094 101.863 -9.177
201703 -7.000 102.862 -8.968
201706 -10.500 103.349 -13.388
201709 -49.000 104.136 -62.006
201712 7.700 104.011 9.755
201803 -6.500 105.290 -8.135
201806 -11.600 106.317 -14.378
201809 -9.300 106.507 -11.506
201812 -9.634 105.998 -11.977
201903 -2.500 107.251 -3.072
201906 -2.300 108.070 -2.805
201909 -3.100 108.329 -3.771
201912 -1.900 108.420 -2.309
202003 -2.000 108.902 -2.420
202006 -1.800 108.767 -2.181
202009 -1.400 109.815 -1.680
202012 -1.400 109.897 -1.679
202103 -1.300 111.754 -1.533
202106 -0.240 114.631 -0.276
202109 -0.250 115.734 -0.285
202112 -0.390 117.630 -0.437
202203 -0.310 121.301 -0.337
202206 -0.280 125.017 -0.295
202209 -0.300 125.227 -0.316
202212 -0.440 125.222 -0.463
202303 -0.300 127.348 -0.310
202306 -0.340 128.729 -0.348
202309 -0.190 129.860 -0.193
202312 -0.330 129.419 -0.336
202403 -0.300 131.776 -0.300

Add all the adjusted EPS together and divide 10 will get our e10.


Theriva Biologics  (AMEX:TOVX) E10 Explanation

If a company grows much fast than inflation, E10 may underestimate the company's earnings power. Shiller PE Ratio can seem to be too high even the actual P/E is low.

For the Shiller P/E, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller P/E is also called PE10.

The Shiller P/E was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.


Be Aware

Shiller PE Ratio works better for cyclical companies. It gives you a better idea on the company's real earnings power.


Theriva Biologics E10 Related Terms

Thank you for viewing the detailed overview of Theriva Biologics's E10 provided by GuruFocus.com. Please click on the following links to see related term pages.


Theriva Biologics (Theriva Biologics) Business Description

Traded in Other Exchanges
Address
9605 Medical Center Drive, Suite 270, Rockville, MD, USA, 20850
Theriva Biologics Inc is a clinical-stage pharmaceutical company developing a novel oncolytic adenovirus (OV) platform to address devastating cancers with high unmet needs. It is a lead clinical-stage program VCN-01, designed to break down the tumor stroma, and its preclinical-stage program VCN-11, leverages its proprietary Albumin Shield Technology to protect systemically administered oncolytic viruses from the host immune system.
Executives
Steven A Shallcross director, officer: CEO and CFO C/O ELYS GAME TECHNOLOGY CORP., 130 ADELAIDE STREET WEST, SUITE 701, TORONTO A6 M5H2K4
Francis Tufaro officer: Chief Operating Officer 9605 MEDICAL CENTER DRIVE SUITE 270, ROCKVILLE MD 20850
John J Monahan director
Scott Tarriff director 28 TUDOR ROSE TERRACE, MAHWAH NJ 07430
Randal J Kirk 10 percent owner 1881 GROVE AVENUE, RADFORD VA 24141
Joseph A. Sliman officer: CHIEF MEDICAL OFFICER 9605 MEDICAL CENTER DRIVE, SUITE 270, ROCKVILLE MD 20850
Jeffrey Scott Riley director C/O ADEONA PHARMACEUTICALS, INC, 3930 VARSITY DRIVE, ANN ARBOR MI 48108
Intrexon Corp 10 percent owner 20374 SENECA MEADOWS PARKWAY, GERMANTOWN MD 20876
Charles Evan Ballantyne officer: CHIEF FINANCIAL OFFICER 27 HEARTHSTONE ROAD, HOPKINTON MA 01748
Nelson K. Stacks director C/O ADEONA PHARMACEUTICALS, INC., 3985 RESEARCH PARK DRIVE, SUITE 200, ANN ARBOR MI 48108
Lyon Lyman Max Jr director, officer: CEO & President C/O ADEONA PHARMACEUTICALS, 3930 VARSITY DRIVE, ANN ARBOR MI 48108
David A. Newsome officer: Chief Scientific Officer 3930 VARSITY DRIVE, C/O PIPEX PHARMACEUTICALS, INC., ANN ARBOR MI 48108
James S Kuo director 509 MADISON AVE 14TH FL, NEW YORK NY 10022
Daniel J Dorman director
Wayne George Holman 10 percent owner 430 PARK AVENUE, 12TH FLOOR, NEW YORK NY 10022

Theriva Biologics (Theriva Biologics) Headlines